Topical skin studies do not establish the effects or safety of injections.
Bottom line: Small human studies tested specific topical products, with mixed findings. They do not establish that injections work better, treat hair loss or improve internal scars. [3–6]
| GHK-Cu topical | GHK-Cu injectable | |
|---|---|---|
| What was studied | Particular topical formulations for facial wrinkles, post-laser skin care and diabetic ulcers. [3–5] | The cited human skin trials did not test injections. [3–5] |
| Mechanism versus benefit | Collagen and tissue-remodeling findings in cell cultures are not proof of a clinical benefit from every serum. [1,2] | The same cell findings do not establish whole-body rejuvenation, hair regrowth or scar treatment from injections. [1,2] |
| Dose and formulation | No universal effective serum concentration follows from these product-specific trials. [3–5] | No routine dose, cycle or preparation recipe is established by these sources. [3–6] |
| Expected results | The wrinkle study lasted eight weeks; the post-laser trial assessed outcomes over 12 weeks. Neither sets a guaranteed response time. [3,4] | The topical studies cannot provide an injection-results timeline. [3–5] |
| Regulatory context | Cosmetic products and ingredients generally do not receive FDA premarket approval, except for certain color additives. [7] | FDA identifies safety concerns for compounded injectable GHK-Cu. A cosmetic product's use does not validate injection. [6,7] |
tierA: {"tier":2,"label":"Limited, formulation-specific human studies"}
tierB: {"tier":1,"label":"Routine injection benefit unestablished"}
summary: The human skin studies cited here used topical products, not injections. Cell experiments cannot establish clinical benefits or demonstrate that either route is superior. [1–5]
trials: [{"name":"Topical facial-wrinkle study","peptide":"a","n":"40 enrolled; 39 completed","finding":"Eight-week, industry-funded study of one formulation. Wrinkle findings favored the GHK-Cu product, but effects cannot be assumed for all serums or injections. [3]"},{"name":"Skin care after CO2 laser resurfacing","peptide":"a","n":"13 completed","finding":"No significant objective advantage in redness, wrinkles or overall skin quality; patient-reported skin quality favored GHK-Cu. [4]","pmid":"16847171"},{"name":"Diabetic-ulcer trial","peptide":"a","n":null,"finding":"Topical gel was studied alongside debridement, pressure-relieving footwear and diabetes education. Findings do not establish injection or cosmetic-scar benefits. [5]","pmid":"17147644"}]
The cited human studies do not support that step. They did not compare the two routes or establish routine injection benefits. [3–5]
No. The human ulcer trial tested topical gel with specialist wound care. The post-laser trial found no significant advantage in redness, wrinkles or objectively assessed skin quality. Neither establishes an injection treatment for scars. [4,5]
These studies did not test that combination. They cannot establish its safety or an effective combined schedule. [3–6]
Cosmetics generally do not receive FDA premarket approval. Cosmetic availability is not drug approval or evidence that a product is suitable for injection. [7]
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
